Drug Combination Details
| General Information of the Combination (ID: C78723) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RRM2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| In-vivo Model | The tumor xenografts were established by injecting 2 * 107 A549 cells per mouse in 100 ul DMEM medium and Matrigel (Corning Inc., Corning, NY) in 1:1 ratio on the dorsal flank of athymic male nude mice (6-8-week-old). | |||||
| Experimental
Result(s) |
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol. 2020 Dec 5;888:173486. | |||
